Selection of HER-2/neu-positive tumor cells in early stage cervical cancer: implications for Herceptin-mediated therapy (Q57218329)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14529687%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

title

Selection of HER-2/neu-positive tumor cells in early stage cervical cancer: implications for Herceptin-mediated therapy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14529687%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

main subject

cervix uterine cancer

1 reference

1 reference

https://api.crossref.org/works/10.1016/S0090-8258(03)00460-8

18 March 2024

author name string

Stefania Bellone

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14529687%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

Michela Palmieri

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14529687%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

Murat Gokden

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14529687%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

Jabbar Joshua

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14529687%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

Sergio Pecorelli

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14529687%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

Juan J. Roman

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14529687

18 March 2024

Martin J. Cannon

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14529687

18 March 2024

Alessandro D. Santin

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14529687

18 March 2024

language of work or name

English

0 references

publication date

1 October 2003

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14529687%20AND%20SRC:MED&resulttype=core&format=json

full work available at URL

19 December 2019

https://api.elsevier.com/content/article/PII:S0090825803004608?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/S0090-8258(03)00460-8

https://api.elsevier.com/content/article/PII:S0090825803004608?httpAccept=text/plain

18 March 2024

1 reference

https://api.crossref.org/works/10.1016/S0090-8258(03)00460-8

18 March 2024

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14529687%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

volume

91

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14529687%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14529687%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

page(s)

231-240

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14529687%20AND%20SRC:MED&resulttype=core&format=json

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

19 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900460-8

7 January 2021

ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900460-8

7 January 2021

Identification of a phosphoprotein specifically induced by the transforming DNA of rat neuroblastomas

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900460-8

7 January 2021

Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900460-8

7 January 2021

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900460-8

7 January 2021

c-erbB-2 Oncoprotein expression is associated with poor prognosis in squamous cell carcinoma of the cervix

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900460-8

7 January 2021

Prognostic significance of the overexpression of c-erbB-2 protein in adenocarcinoma of the uterine cervix

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900460-8

7 January 2021

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900460-8

7 January 2021

Correlation of cervical carcinoma c-erb B-2 oncogene with cell proliferation parameters in patients treated with radiation therapy for cervical carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900460-8

7 January 2021

HER-2/neu oncogene amplification in cervical cancer studied by fluorescent in situ hybridization

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900460-8

7 January 2021

Development and characterization of an IL-4-secreting human ovarian carcinoma cell line

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900460-8

7 January 2021

Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900460-8

7 January 2021

Lymphocyte subset distribution after radiation therapy for cancer of the uterine cervix. Possible prognostic implications and correlation with disease course

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900460-8

7 January 2021

Effects of concurrent cisplatinum administration during radiotherapy vs. radiotherapy alone on the immune function of patients with cancer of the uterine cervix

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900460-8

7 January 2021

Lymphokine-activated killer cells targeted by monoclonal antibodies to the disialogangliosides GD2 and GD3 specifically lyse human tumor cells of neuroectodermal origin

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900460-8

7 January 2021

Fc receptors are required in passive and active immunity to melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900460-8

7 January 2021

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900460-8

7 January 2021

Sporadic amplification of the HER2/neu protooncogene in adenocarcinomas of various tissues

6

1 reference

https://api.crossref.org/works/10.1016/S0090-8258(03)00460-8

Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer

18 March 2024

8

1 reference

https://api.crossref.org/works/10.1016/S0090-8258(03)00460-8

Expression of epidermal growth factor receptor and HER-2/neu in normal and neoplastic cervix, vulva, and vagina

18 March 2024

15

1 reference

https://api.crossref.org/works/10.1016/S0090-8258(03)00460-8

Eradication of large human B cell tumors in nude mice with unconjugated CD20 monoclonal antibodies and interleukin 2

18 March 2024

19

1 reference

https://api.crossref.org/works/10.1016/S0090-8258(03)00460-8

18 March 2024

Identifiers

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14529687%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

1 reference